In April of this year, Takeda Pharmaceutical, Japan’s largest drug company purchased Millennium Pharmaceuticals, one of the earliest American genomics companies for nearly $9 billion providing Takeda an entry into the cancer-drug market. During this off-the-record discussion, topics will include:
- Important criteria each company sought in a strategic partner
- Communicating effectively through cultural differences
- Lessons learned during the due diligence process
- Approach for successful integration of the two companies
Presenters included:
- Gabor Garai, Co-Chair, Life Sciences Industry Team, Foley
- Dr. Daniel Curran, Vice President, Corporate Development, Millennium Pharmaceuticals Inc.
- Catherine Sazdanoff, Vice President, Global Licensing, Takeda Pharmaceuticals North America, Inc.
Related Insights
July 8, 2025
Energy Current
What’s the Future for Renewable Energy Tax Credits in Congress?
The One Big Beautiful Bill Act (OBBB) has a significant impact on the renewable energy sector, particularly with changes in the phase-out…
July 8, 2025
Energy Current
Executive Order on PTC and ITC Beginning of Construction
President Trump yesterday issued an executive order, “Ending Market Distorting Subsidies for Unreliable, Foreign Controlled Energy…
July 8, 2025
Foley Viewpoints
The HDHP Telehealth Safe Harbor Returns – For Good This Time
President Trump signed into law the One Big Beautiful Bill Act (the bill) on July 4, 2025. The telehealth safe harbor, which allowed…